Aldeyra announces FDA acceptance of resubmitted reproxalap application
Aldeyra (ALDX) announced FDA acceptance of its resubmitted market application for reproxalap and an expansion of its option agreement with AbbVie (ABBV). Read more here.
Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application
Shares of Aldeyra Therapeutics gained after the Food and Drug Administration accepted the company's resubmitted new drug application for its treatment of dry eye disease for review. The stock rose 11% ...
Monthly Prescribing Reference19h
Reproxalap Under Review Again for Dry Eye Disease
A Prescription Drug User Fee Act date of April 2, 2025 has been assigned to the resubmitted application. The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug ...
AbbVie snaps eight straight sessions of losses
AbbVie (NYSE:ABBV) shares snapped eight consecutive sessions of losses as the stock closed up 0.78% at $166.28. The North ...